CLINICAL_TRIALS
trial_result
· 2018-06-25
Clinical Trial Update: A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants [Phase 2]
Summary
Phase 2 trial update for emibetuzumab in non-small cell lung cancer has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2018-06-25